Fluorescent Footprint for Hematology Cell Identification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hematology analyzers face challenges in accurately performing a comprehensive five-part white blood cell differential, especially in the presence of atypical leukocyte populations or abnormal conditions, leading to high false positive or false negative rates and requiring manual review or missed clinically significant abnormalities.
Innovation Solution
The use of unique combinations of fluorochrome-labeled antibodies and fluorescent dyes with overlapping spectra that cannot be separated by optical or electronic compensation methods, creating a new fluorescent footprint for identifying additional cell populations or subtypes in hematological disease, allowing for the enumeration of multiple cell populations in a single analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional hematology instruments use standard fluorochrome-labeled antibodies with separable emission spectra, then optical or electronic compensation methods can separate the spectra into individual components, but this limits the ability to identify additional cell populations or subtypes in hematological disease
Solution Approach 1:
The patent changes the spectral parameter by using fluorochrome-labeled antibodies with overlapping emission spectra that cannot be separated by conventional optical or electronic compensation methods. This creates a new fluorescent footprint that preserves information about multiple cell populations simultaneously, enabling identification of additional cell subtypes while maintaining spectral information that would otherwise be lost.
2Productivity
If multiple fluorochrome-labeled antibodies with non-overlapping spectra are used, then each antibody can be independently detected and compensated, but this requires multiple separate analyses and cannot enumerate multiple cell populations in a single analysis
Solution Approach 1:
The patent merges multiple fluorochrome-labeled antibodies with overlapping spectra into a single reaction mixture that can be analyzed simultaneously. This combination creates a new fluorescent footprint that allows enumeration of multiple cell populations in one analysis, increasing productivity while the overlapping spectra design simplifies the instrument configuration by eliminating the need for multiple separate detection systems.
3Measurement precision
If conventional hematology analyzers perform five-part white blood cell differential, then normal mature cell types can be differentiated, but atypical or immature cells cannot be readily identified, requiring manual review
Solution Approach 1:
The patent introduces fluorochrome-labeled antibodies with overlapping spectra as an intermediary that binds to specific cell surface antigens on atypical or immature cells. This intermediary approach enables the automated instrument to detect and differentiate these abnormal cell populations by their unique fluorescent footprints, improving measurement precision for atypical cells while maintaining automation and eliminating the need for manual review.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables rapid and accurate identification of multiple cell populations, including atypical and immature cells, reducing false rates and improving diagnostic accuracy in hematological analysis with minimal manual review.
Implementation Method 1
The use of unique combinations of fluorochrome-labeled antibodies and fluorescent dyes with overlapping spectra that cannot be separated by optical or electronic compensation methods, creating a new fluorescent footprint for identifying additional cell populations or subtypes in hematological disease
Data Source
AI summary
Methods for differentially identifying cells in an instrument employ compositions containing a combination of selected antibodies and fluorescent dyes having different cellular distribution patterns and specificities, as well as antibodies and fluorescent dyes characterized by overlapping emission spectra which form non-compensatable spectral patterns. When utilizing the compositions described herein consisting of fluorescent dyes and fluorochrome labeled antibodies with overlapping spectra that cannot be separated or distinguished based upon optical or electronic compensation means, a new fluorescent footprint is established. This new fluorescent footprint is a result of the overlapping spectra and the combined cellular staining patterns of the dyes and fluorochrome labeled antibodies chosen for the composition. The new fluorescent footprint results in histogram patterns that are useful for the identification of additional cell populations or subtypes in hematological disease.